These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 31101066)

  • 1. The promise of Immuno-oncology: implications for defining the value of cancer treatment.
    Kaufman HL; Atkins MB; Subedi P; Wu J; Chambers J; Joseph Mattingly T; Campbell JD; Allen J; Ferris AE; Schilsky RL; Danielson D; Lichtenfeld JL; House L; Selig WKD
    J Immunother Cancer; 2019 May; 7(1):129. PubMed ID: 31101066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Customer pyramid framework for CAR T-cell therapies in immuno-oncology.
    Malik NN; Durdy MB
    Drug Discov Today; 2016 Oct; 21(10):1563-1565. PubMed ID: 27640934
    [No Abstract]   [Full Text] [Related]  

  • 3. Advanced APMs and the emerging role of immuno-oncology agents: balancing innovation and value.
    Seiden MV; Neubauer M; Verrilli D
    Am J Manag Care; 2017 Feb; 23(2 Spec No.):SP69-SP77. PubMed ID: 28298130
    [No Abstract]   [Full Text] [Related]  

  • 4. Trends in treatment patterns and survival outcomes in advanced non-small cell lung cancer: a Canadian population-based real-world analysis.
    Carroll R; Bortolini M; Calleja A; Munro R; Kong S; Daumont MJ; Penrod JR; Lakhdari K; Lacoin L; Cheung WY
    BMC Cancer; 2022 Mar; 22(1):255. PubMed ID: 35264135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical development of immuno-oncology in China.
    Wu DW; Huang HY; Tang Y; Zhao Y; Yang ZM; Wang J; Wang SH; Yu Y; Fang Y; Fang H; Bai Y; Sun C; Fan Q; Yu AQ; Wang HL; Du CX; Chen K; Huang MD; Zhang Y; Li N; Xu BH; Sun Y; He J
    Lancet Oncol; 2020 Aug; 21(8):1013-1016. PubMed ID: 32758460
    [No Abstract]   [Full Text] [Related]  

  • 8. Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity.
    Anagnostou V; Yarchoan M; Hansen AR; Wang H; Verde F; Sharon E; Collyar D; Chow LQM; Forde PM
    Clin Cancer Res; 2017 Sep; 23(17):4959-4969. PubMed ID: 28864724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The hubris and humility of cancer pharmacology in the post immuno-oncology era.
    Lazo JS
    Pharmacol Res Perspect; 2019 Dec; 7(6):e00527. PubMed ID: 31624635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Master protocols in immuno-oncology: do novel drugs deserve novel designs?
    Mazzarella L; Morganti S; Marra A; Trapani D; Tini G; Pelicci P; Curigliano G
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32238471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contrasting evidence to reimbursement reality for off-label use (OLU) of drug treatments in cancer care: rationale and design of the CEIT-OLU project.
    Herbrand AK; Schmitt AM; Briel M; Diem S; Ewald H; Hoogkamer A; Joerger M; Mc Cord KA; Novak U; Sricharoenchai S; Hemkens LG; Kasenda B
    ESMO Open; 2019; 4(6):e000596. PubMed ID: 31803503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer Nanomedicine: Lessons for Immuno-Oncology.
    Sengupta S
    Trends Cancer; 2017 Aug; 3(8):551-560. PubMed ID: 28780932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health-related quality-of-life assessment of patients with solid tumors on immuno-oncology therapies.
    Voon PJ; Cella D; Hansen AR
    Cancer; 2021 May; 127(9):1360-1368. PubMed ID: 33662145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The revolution of immuno-oncology therapy: specificities for the physicians].
    Dubois M; Ardin C; André F; Scherpereel A; Mortier L
    Med Sci (Paris); 2019 Dec; 35(12):946-948. PubMed ID: 31903898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. End points and statistical considerations in immuno-oncology trials: impact on multiple myeloma.
    Hoering A; Durie B; Wang H; Crowley J
    Future Oncol; 2017 Jun; 13(13):1181-1193. PubMed ID: 28395525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The changing face of clinical trials in the personalized medicine and immuno-oncology era: report from the international congress on clinical trials in Oncology & Hemato-Oncology (ICTO 2017).
    Golan T; Milella M; Ackerstein A; Berger R
    J Exp Clin Cancer Res; 2017 Dec; 36(1):192. PubMed ID: 29282151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug Treatment Value in a Changing Oncology Landscape: A Literature and Provider Perspective.
    Frois C; Howe A; Jarvis J; Grice K; Wong K; Zacker C; Sasane R
    J Manag Care Spec Pharm; 2019 Feb; 25(2):246-259. PubMed ID: 30698093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends and challenges in immuno-oncology trials.
    Kiernan B
    Drugs Today (Barc); 2016 Jul; 52(7):387-93. PubMed ID: 27540597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Precision Medicine in Oncology II: Economics of Targeted Agents and Immuno-Oncology Drugs.
    Huntington SF; Davidoff AJ; Gross CP
    J Clin Oncol; 2020 Feb; 38(4):351-358. PubMed ID: 31804866
    [No Abstract]   [Full Text] [Related]  

  • 20. Addressing current challenges and future directions in immuno-oncology: expert perspectives from the 2017 NIBIT Foundation Think Tank, Siena, Italy.
    Maio M; Coukos G; Ferrone S; Fox BA; Fridman WH; Garcia PL; Lahn M; Provendier O; Russo V; Rüttinger D; Shalabi A; Trajanoski Z; Viallet J; Wolchok JD; Ibrahim R
    Cancer Immunol Immunother; 2019 Jan; 68(1):1-9. PubMed ID: 30564889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.